Session I - Biology

Mutations in BCR::ABL1 and beyond
S. Soverini, Bologna
Is BCR::ABL1 the key target in all CML patients?
K. Machova-Polakova, Prague, Czech Republic
Biology of Ph+ ALL: new insights for risk stratification
I. Iacobucci, Memphis, USA
Beyond the Ph+ cell: the role of microenvironment
A. Curti, Bologna
Session II - First line approaches in 2025

ELN 2025 recommendations
D. Milojkovic, London, United Kingdom
New drugs in first-line CML treatment
M. Breccia, Rome
Chemo-free approach of Ph+ ALL
S. Chiaretti, Rome
How should we monitor MRD in Ph+ ALL: BCR-ABL or IgH/TCR?
R. Kim, Paris, France
Lecture I

CML and Ph+ ALL: what’s new @ MDACC
E.J. Jabbour, Houston, USA
Session III - Hot topics in 2025

New challenges in treatment-free remission
F. Nicolini, Lyon, France
Advanced phase CML
C. Fava, Turin
Ph like ALL: diagnosis and treatment
G. Martinelli, Bologna
Allo-SCT in Ph+ ALL: is it still necessary?
A. Rambaldi, Bergamo
Session IV: Later lines and relapsed disease

Second and third-line therapy in CML
V. Garcia-Gutierrez, Madrid, Spain
Treatment of CML patients with high cardiovascular risk
G. Caocci, Cagliari
TKI based approach in R/R Ph+ ALL
M. Bonifacio, Verona
Antibodies in R/R Ph+ ALL: present and future
C. Papayannidis, Bologna
Session V: Future of Ph+ leukemias treatment

Novel agents for the treatment of CML
M. Tiribelli, Udine
New immunotherapy strategies in Ph+ ALL
F. Lussana, Modena
Lecture II

CAR-T cells in ALL: present and pitfalls
C. Roddie, London, United Kingdom
Privacy Policy | Cookie Policy